Shire is a holding company. Through its subsidiaries, Co. operates as a biotechnology company focused on serving people with rare diseases and other conditions. Co.'s portfolio covers seven therapeutic areas: Immunology, Hematology, Neuroscience, Internal Medicine (IM), Genetic Diseases, Oncology, and Ophthalmics. Some of Co.'s marketed products include GAMMAGARD, HYQVIA and CINRYZE for Immunology, ADVATE/ADYNOVATE, VONVENDI and FEIBA for Hematology, VYVANSE and ADDERALL XR for Neuroscience, LIALDA/MEZAVANT and PENTASA for IM, ELAPRASE and REPLAGAL for Genetic Diseases, ONCASPAR and ONYVIDE for Oncology and XIIDRA for Ophthalmics. When considering the Shire Plc (Jersey) stock dividend history, we have taken known splits into account, such that the SHPG dividend history is presented on a split-adjusted ("apples to apples") basis. Shire Plc (Jersey) dividend history is presented both in graphical/chart form, and as a SHPG dividend history data table along the right-hand column.
|
SHPG Stock Dividend HistoryThe SHPG dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable SHPG historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the SHPG dividend history record. Also see the SHPG stock dividend history data table along the right-hand column below. |
|
SHPG Next Dividend Date » (Projection based upon history) Quotes delayed 20 minutes |
Buy (3.11 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
Projection: SHPG Next Dividend Date Chart: SHPG Chart - 5Yr Dividend Yield |